The authors administered tiaprid (Tiapridal, Delagrange), to six patients with the dyskinetic form of cerebral palsy, mean dose 11.4 mg/kg/day in three portions. In five instances clinical improvement was recorded, all patients improved as regards tests of practical skills. On the EEG during tiaprid treatment reduction of muscular artefacts was recorded. By means of an original testing device the authors revealed that tiaprid exerts a relatively small influence on the reaction time in response to a light stimulus but that it prolongs significantly the time needed for the motor performance proper. More marked undesirable effects were manifested in one patient (subjectively reported short-term change of sensitivity of the lower extremities and increased amplitude of dyskinesias). The authors emphasize the positive properties of the preparation and recommend tiaprid as the drug of first choice for pharmacological inhibition of extrapyramidal hyperkinesias in patients with the dyskinetic form of cerebral palsy in children.

Výzkumný ústav zdraví dítĕte Brno